Itch, sleep loss, depressive symptoms, fatigue, and productivity loss in patients with moderate-to-severe atopic dermatitis: Analyses of TREATgermany registry data.
Atopic dermatitis
productivity loss
registry
work limitations
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
30
01
2023
accepted:
28
05
2023
medline:
23
10
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
ppublish
Résumé
TREATgermany is a multicenter registry including patients with moderate-to-severe atopic dermatitis (AD) from currently 74 study centers (university clinics, hospitals and practices) in Germany. As of August 31, 2021, 1,230 adult patients were enrolled. In TREATgermany, patients and physicians fill in questionnaires pertaining to symptoms, disease severity, quality of life, depressiveness, and fatigue. In particular, limitations in work performance are assessed using the Work Limitations Questionnaire (WLQ). To assess associations between occupational performance/work limitations and symptoms, correlations and regression models were calculated. The examined sample of 228 employed patients reported an average of 6% at-work productivity loss within the past two weeks prior to enrolment in the registry. The WLQ productivity loss score was moderately associated with itch (r = 0.32) and sleep loss (r = 0.39) and strongly associated with depressive symptoms (r = 0.68) and fatigue (r = 0.60). The analyses of the registry data show that moderate-to-severe atopic dermatitis has a negative impact on the work productivity of the patients. The analyses further point out the relevant associations between work productivity, depressive symptoms, and fatigue highlighting the disease burden caused by the psychological components of AD.
Sections du résumé
BACKGROUND
TREATgermany is a multicenter registry including patients with moderate-to-severe atopic dermatitis (AD) from currently 74 study centers (university clinics, hospitals and practices) in Germany. As of August 31, 2021, 1,230 adult patients were enrolled.
METHODS
In TREATgermany, patients and physicians fill in questionnaires pertaining to symptoms, disease severity, quality of life, depressiveness, and fatigue. In particular, limitations in work performance are assessed using the Work Limitations Questionnaire (WLQ). To assess associations between occupational performance/work limitations and symptoms, correlations and regression models were calculated.
RESULTS
The examined sample of 228 employed patients reported an average of 6% at-work productivity loss within the past two weeks prior to enrolment in the registry. The WLQ productivity loss score was moderately associated with itch (r = 0.32) and sleep loss (r = 0.39) and strongly associated with depressive symptoms (r = 0.68) and fatigue (r = 0.60).
CONCLUSIONS
The analyses of the registry data show that moderate-to-severe atopic dermatitis has a negative impact on the work productivity of the patients. The analyses further point out the relevant associations between work productivity, depressive symptoms, and fatigue highlighting the disease burden caused by the psychological components of AD.
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1157-1168Informations de copyright
© 2023 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345-360.
Siegels D, Heratizadeh A, Abraham S, et al. Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. Allergy. 2021;76:1053-1076.
Zietze HA, Cabral C, Theobald K, et al. Epidemiology and treatment of adult patients with atopic dermatitis : Analysis of longitudinal data of the statutory health insurance scheme. Hautarzt. 2021;72:963-974.
Gilaberte Y, Pérez-Gilaberte JB, Poblador-Plou B, et al. Prevalence and comorbidity of atopic dermatitis in children: a large-scale population study based on real-world data. J Clin Med. 2020;9:1632.
Stingeni L, Belloni Fortina A, Baiardini I, et al. Atopic dermatitis and patient perspectives: insights of bullying at school and career discrimination at work. J Asthma Allergy 2021;14:919-928.
Talamonti M, Galluzzo M, Silvaggio D, et al. Quality of life and psychological impact in patients with atopic dermatitis. J Clin Med. 2021;10:1298.
Bruin-Weller M, Pink AE, Patrizi A, et al. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. J Dermatol Treat. 2021;32:164-173.
Helmert C, Haufe E, Heinrich L, et al. Atopic dermatitis and depressive symptoms. Results of the German national AD Registry TREATgermany. J Eur Acad Dermatol Venereol. 2021;36:e279-e282.
Legat FJ. Itch in Atopic dermatitis - what is new? Front Med 2021;8:644-760.
Bonnekoh H, Butze M, Metz M. Characterization of the effects on pruritus by novel treatments for atopic dermatitis. J Dtsch Dermatol Ges. 2022;20:150-156.
Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol. 2018;19:821-838.
Werfel T, Heratizadeh A, Aberer W, et al. S2k guideline on diagnosis and treatment of atopic dermatitis-short version. J Dtsch Dermatol Ges. 2016;14:92-106.
Werfel T, Heratizadeh A, Aberer W, et al. Update “Systemic treatment of atopic dermatitis” of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges. 2021;19:151-168.
Worm M, Francuzik W, Kraft M, Alexiou A. Modern therapies in atopic dermatitis: biologics and small molecule drugs. J Dtsch Dermatol Ges. 2020;18:1085-1092.
Zhou S, Qi F, Gong Y, et al. Biological therapies for atopic dermatitis: a systematic review. Dermatology. 2021;237:542-552.
Sawangjit R, Dilokthornsakul P, Lloyd-Lavery A, et al. Systemic treatments for eczema: a network meta-analysis. Cochrane Database Syst Rev. 2020;9:Cd013206.
Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156:659-667.
Bosma AL, Musters AH, Bloem M, et al. Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema (TREAT) Registry Taskforce. J Eur Acad Dermatol Venereol. 2022;00:1-14.
Heratizadeh A, Haufe E, Stölzl D, et al. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. J Eur Acad Dermatol Venereol. 2020;34:1263-1272.
Williams HC, Burney PG, Strachan D, Hay RJ. The U.K. working party's diagnostic criteria for atopic dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol 1994;131:397-405.
Williams HC, Burney PG, Hay RJ, et al. The U.K. working party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131:383-396.
Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195:10-19.
Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol. 2007;157:645-648.
Schmitt J, Langan S, Deckert S, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 2013;132:1337-1347.
Werfel T, Aberer W, Ahrens F, et al. Leitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis]. J Dtsch Dermatol Ges. 2016;14:e1-75.
Grinich EE, Schmitt J, Kuester D, et al. Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative. Br J Dermatol. 2018;179:540-541.
Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10:11-18.
Tofte S, Graeber M, Cherill R, et al. Eczema area and severity index (EASI): A new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol. 1998;11:197.
Spuls PI, Gerbens LAA, Simpson E, et al. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol. 2017;176:979-984.
Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169:1326-1332.
Schram ME, Spuls PI, Leeflang MM, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67:99-106.
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004;140:1513-1519.
Chalmers JR, Simpson E, Apfelbacher CJ, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2016;175:69-79.
Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc. 2004;9:169-180.
Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol. 2002;147:50.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-216.
Schmitt J, Apfelbacher C, Spuls PI, et al. The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. J Invest Dermatol. 2015;135:24-30.
Schmitt J, Spuls PI, Thomas KS, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134:800-807.
Stalder J, Taieb A, Atherton D, et al. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186:23-31.
Futamura M, Leshem YA, Thomas KS, et al. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. J Am Acad Dermatol. 2016;74:288-294.
Friedli T, Villiger PM, Gantschnig BE. Workability for persons with chronic diseases. A systematic review of validity and utility of assessments in German language. IJHP. 2018;5:72-90.
Lerner D, Reed JI, Massarotti E, et al. The Work Limitations Questionnaire's validity and reliability among patients with osteoarthritis. J Clin Epidemiol. 2002;55:197-208.
Lerner D, Amick BC, 3rd, Rogers WH, et al. The Work Limitations Questionnaire. Med Care. 2001;39:72-85.
Rodríguez MR, Nuevo R, Chatterji S, Ayuso-Mateos JL. Definitions and factors associated with subthreshold depressive conditions: a systematic review. BMC psychiatry. 2012;12:1-7.
Thombs BD, Hudson M, Schieir O, et al. Reliability and validity of the center for epidemiologic studies depression scale in patients with systemic sclerosis. Arthritis Rheum. 2008;59:438-443.
Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl Psychol Meas. 1977;1:385-401.
Valko PO, Bassetti CL, Bloch KE, et al. Validation of the fatigue severity scale in a Swiss cohort. Sleep. 2008;31:1601-1607.
Reske D, Pukrop R, Scheinig K, et al. Measuring fatigue in patients with multiple sclerosis with standardized methods in German speaking areas. Fortschritte Neurol Psychiatr. 2006;74:497-502.
Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177:1316-1321.
Pfeffer A. Einsatz bei Erschöpfung. Physiopraxis 2008;6:42-43.
Lerner D, Amick BC, 3rd, Lee JC, et al. Relationship of employee-reported work limitations to work productivity. Med Care. 2003;41:649-659.
Cohen J. Statistical power analysis for the behavioral sciences. 2. Edition. Erlbaum, 1988.
R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: https://www.R-project.org/. [Last accessed April 25, 2023]
Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4:1.
Weisshaar E, Bentz P, Apfelbacher C, et al. Itching in atopic dermatitis: patient- and physician-reported outcomes in the German atopic dermatitis registry TREATgermany. Acta Derm-Venereo.l 2023;103:adv00854.
Weisshaar E, Bentz P, Haufe E, et al. Itching and treatments in Atopic Dermatitis (AD): Results from the German AD Registry TREATgermany. Br J Dermatol. 2022;188:430-432.
Kage P, Simon JC, Treudler R. Atopische Dermatitis und psychosoziale Komorbidität. J Dtsch Dermatol Ges. 2020;18(2):93-102.
Kage P, Zarnowski J, Simon J-C, Treudler R. Atopic dermatitis and psychosocial comorbidities - What's new? Allergologie select. 2020;4:86-96.
Li JC, Fishbein A, Singam V, et al. Sleep disturbance and sleep-related impairment in adults with atopic dermatitis: A cross-sectional survey-based study. Dermatitis. 2018;29:270.
Marron S, Cebrian-Rodriguez J, Alcalde-Herrero V, et al. Psychosocial impact of atopic dermatitis in adults: a qualitative study. Actas Dermo-Sifilogr. 2020;111:513-517.
Nicholas MN, Gooderham MJ. Atopic dermatitis, depression, and suicidality. J Cutan Med Surg. 2017;21:237-242.
Ring J, Zink A, Arents BWM, et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol. 2019;33:1331-1340.
Rønnstad ATM, Halling-Overgaard AS, Hamann CR, et al. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;79:448-456.e430.
Thyssen JP, Hamann CR, Linneberg A, et al. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy. 2018;73:214-220.
Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123:144-151.
Silverberg JI. Associations between atopic dermatitis and other disorders. F1000Res. 2018;7:303.
Ariëns LFM, van Nimwegen KJM, Shams M, et al. Economic burden of adult patients with moderate to severe atopic dermatitis indicated for systemic treatment. Acta Derm-Venereol. 2019;99:762-768.
Haufe E, Abraham S, Heratizadeh A, et al. Verminderte berufliche Leistungsfähigkeit und Lebensqualität bei Patienten mit moderater bis schwerer Neurodermitis - Ergebnisse aus dem Deutschen Neurodermitisregister TREATgermany. Hautarzt. 2018;69:815-824.
Lerner D, Adler DA, Chang H, et al. The clinical and occupational correlates of work productivity loss among employed patients with depression. J Occup Environ Med. 2004;46:S46-55.
Chopra R, Vakharia PP, Sacotte R, et al. Relationship between EASI and SCORAD severity assessments for atopic dermatitis. J Allergy Clin Immunol. 2017;140:1708-1710.e1701.
Haufe E, Abraham S, Heratizadeh A, et al. Verminderte berufliche Leistungsfähigkeit und Lebensqualität bei Patient/innen mit moderater bis schwerer Neurodermitis - Ergebnisse aus dem Deutschen Neurodermitisregister TREATgermany. Allergologie. 2019;42:266-274.